As research progresses, further study of the mechanisms and prevalence of MDM2 amplification in pancreatic cancer, and ongoing clinical trials will provide valuable insights into optimizing the efficacy and safety of MDM2-targeted therapies [62]. The gene discussed is MDM2; the disease is familial pancreatic carcinoma.